GleamWall
中文EN

WHWK Whitehawk Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1422142 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-72.5%
TTM net income YoY67.7%
TTM EPS YoY86.0%
Revenue 3-yr CAGR-22.3%
Net income 3-yr CAGR—

Margins

Gross margin89.4%
Operating margin-1,601.1%
Net margin-288.3%
FCF margin-1,371.4%
EBITDA margin-1,600.0%

Returns

ROE-21.8%
ROA-18.6%
ROIC (approx.)-147.5%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets9.6%
Debt / equity0.00x
Current ratio10.26x
Interest coverage—

Cash quality & payout

Operating cash flow / net income4.73x
Accruals ratio69.5%
Payout ratio—
Capex / revenue7.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$7.14M$7.24M
Cost of revenue$0$0$0$0$0$0$760,000$790,000
Gross profit$0$0$0$0$0$0$6.38M$6.45M
R&D expense$18.14M$12.89M$17.23M$19.02M$14.35M$48.81M$8.79M$14.35M
SG&A expense$4.80M$5.22M$6.29M$5.87M$5.20M$5.94M$12.81M$11.05M
Operating income-$22.94M-$18.11M-$23.52M-$24.89M-$19.55M-$54.75M-$15.22M-$18.95M
Interest expense———$0$0$0$0$0
Pretax income-$21.21M-$16.64M-$22.19M-$23.25M-$17.75M-$52.62M$73.02M—
Income tax$0$0$0$0$0$0$0$0
Net income-$21.21M-$16.64M-$22.19M-$23.25M-$17.75M-$52.62M$73.02M-$18.27M
EBITDA-$22.94M-$18.11M-$23.52M-$24.89M-$19.54M-$54.73M-$15.16M-$18.90M
EPS (basic)-0.23-0.20-0.32—-0.26-0.761.84—
EPS (diluted)-0.23-0.20-0.32—-0.26-0.761.83—
Weighted avg. shares (diluted)93.87M82.89M69.24M—69.20M69.08M39.93M—
Balance sheet
Cash & equivalents$68.97M$85.23M$34.79M$37.57M$37.93M$144.94M$227.57M$28.67M
Short-term investments$100.70M$104.75M$88.25M$108.13M$124.67M$32.26M$3.49M$18.57M
Receivables———$0$0$0$0$5.90M
Inventory———$0$0$0$0$5.31M
Current assets$171.97M$192.41M$125.55M$149.01M$165.04M$178.67M$232.61M$61.29M
PP&E, net$3,000$1,000$2,000$3,000$4,000$9,000$25,000$6.85M
Total assets$173.69M$193.99M$127.23M$150.83M$167.02M$180.82M$234.00M$70.32M
Current liabilities$10.44M$11.07M$11.06M$14.52M$9.85M$8.76M$12.27M$17.07M
Total liabilities$10.53M$11.07M$11.06M$14.52M$9.85M$8.76M$12.27M$17.84M
Shareholders' equity$163.16M$182.93M$116.17M$136.31M$157.17M$172.07M$221.73M$52.48M
Shares outstanding59.01M57.01M47.20M47.15M47.13M47.13M46.78M24.68M
Cash flow statement
Operating cash flow-$19.67M-$14.53M-$22.21M-$17.23M-$15.38M-$52.96M-$11.86M-$15.05M
Capital expenditure$3,000$0$0$0$0$1,000$551,000$186,000
Free cash flow-$19.68M-$14.53M-$22.21M-$17.23M-$15.38M-$52.96M-$12.41M-$15.24M
Investing cash flow$3.61M-$16.87M$19.43M$16.85M-$91.63M-$28.83M$115.50M$13.13M
Financing cash flow-$194,000$81.84M$0$25,000$0-$850,000$95.20M$53,000
Depreciation & amortization$800$1,000$1,000$1,000$5,600$15,300$57,000$47,000
Stock-based compensation$1.75M$1.52M$2.19M$2.39M$2.72M$3.09M$1.68M$1.85M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.